Alkem's Q2/H1 FY26 earnings call covers U.S. CDMO vs. Pune contributions, opex guidance for Q3/Q4, R&D phasing to 4–5%, penicillin G pricing speculation, and a spike in other expenses.
AI Assistant
Alkem Laboratories Ltd
2025
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.